Coagulation abnormalities in cystic fibrosis.
D000900:Anti-Bacterial Agents / Q000494:pharmacology; D001772:Blood Cell Count; D001777:Blood Coagulation / Q000187:drug effects; D001778:Blood Coagulation Disorders / Q000188:drug therapy / Q000209:etiology*; D001780:Blood Coagulation Tests; D001792:Blood Platelets; D002648:Child; D003550:Cystic Fibrosis / Q000150:complications* / Q000503:physiopathology; D005342:Fibrinolysis; D006471:Gastrointestinal Hemorrhage / Q000150:complications; D006469:Hemoptysis / Q000150:complications; D006529:Hepatomegaly / Q000209:etiology; D006801:Humans; D008099:Liver / Q000503:physiopathology; D008111:Liver Function Tests; D008168:Lung / Q000503:physiopathology; D011446:Prospective Studies; D011517:Prothrombin Time; D013163:Splenomegaly / Q000209:etiology; D013921:Thrombocytopenia / Q000209:etiology; D013925:Thromboplastin / Q000032:analysis; D014812:Vitamin K / Q000627:therapeutic use
D000900:Anti-Bacterial Agents; D014812:Vitamin K; D013925:Thromboplastin